References - Anti-VEGF in the treatment of AMD


57. NICE Final Guidance. Ranibizumab and pegaptanib for age-related macular degeneration. At
58. Sadda S. HORIZON extension trial of ranibizumab for neovascular age-related macular
degeneration: First-year safety and efficacy results. Presented at the Annual Meeting of the Retina

59. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group. Ranibizumab combined with
verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year

neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch
Ophthalmol 2002; 120 (3): 338 -46

61. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular

62. Sivaprasad S. Role of pegaptanib sodium in the treatment of neovascular age-related macular

63. Waheed NK, Miller JW. Aptamers, intramers, and vascular endothelial growth factor. Int Ophthalmol

Pharmacother. (2008) 9(3) 507 from a safety-pharmacokinetic trial in patients with neovascular

65. Apte RS. Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin

growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys.

67. Eyetech Study Group. Preclinical and Phase 1A clinical evaluation of an anti-VEGF pegylated
aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;
22 (2): 143 -52.

68. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal
neovascularisation secondary to age-related macular degeneration: Phase II study results.
Ophthalmology 2003; 110 (5): 979 -86

69. Ruckman J, Green LS, Beeson J, et al. 2 -Fluoropyrimidine RNA-based aptamers to the 165-amino
acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-
induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol

70. Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group.
Enhanced efficacy associated with early treatment of neovascular age-related macular
degeneration with pegaptanib sodium: an exploratory analysis. Retina. 2005 Oct-Nov; 25(7):815-
27.

71. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related

72. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized
controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
Ophthalmology 2006; 113 (9): 1508, e1501-25.

degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

74. Suner IJ. Safety of pegaptanib sodium in age-related macular degeneration (AMD): 3-year results of
the VISION trial. Annual Meeting of the American Academy of Ophthalmology, Las Vegas, Nevada;
2006.

75. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular


View PDF